Rami Elghandour, President of Arcellx (NASDAQ:ACLX), sold 89,916 shares for approximately $10.24 million on Feb. 27, 2026, according to a SEC Form 4 filing.
|
Metric |
Value |
|---|---|
|
Shares sold (direct) |
89,916 |
|
Transaction value |
$10.2M |
|
Post-transaction shares (direct) |
276,051 |
|
Post-transaction shares (indirect) |
416,500 |
|
Post-transaction value (direct ownership) |
~$31.41M |
Transaction value based on SEC Form 4 weighted average purchase price ($113.92); post-transaction value based on Feb. 27, 2026 market close ($113.79).
-
How does this transaction compare to Elghandour’s previous sell activity?
This sale of 89,916 shares is notably larger than his historical median sell size of 38,300 shares since January 2025. -
What impact does the sale have on the insider’s ownership profile?
Following the sale, Elghandour retains 276,051 shares in direct ownership and maintains 416,500 shares indirectly through a spousal trust, resulting in continued material exposure to Arcellx equity.
|
Metric |
Value |
|---|---|
|
Price |
$113.79 |
|
Market capitalization |
$6.65 billion |
|
Net Loss (TTM) |
-$228.93 million |
|
1-year price change |
75.55% |
*Price and 1-year performance are calculated using Feb. 28, 2026, as the reference date.
Arcellx, Inc. is a clinical-stage biotechnology company specializing in innovative immunotherapies for cancer and other incurable diseases. The company primarily works with oncology healthcare providers and patients with difficult-to-treat cancers across the United States and select global markets.
Although ACLX share prices have soared, the stock will soon be delisted, as on Feb. 23, 2026, the company announced that it would be acquired by Gilead Sciences (NASDAQ:GILD), another global biopharmaceutical company. While there is no current expected date for the transaction to be finalized, the acquisition is estimated to be worth $7.8 billion, with Gilead purchasing Arcellx at $115 per share and a contingent value right of $5 per share.
The immunotherapy provider also recently achieved a breakthrough with one of its top clinical-stage projects, advancing its multiple myeloma treatment to Phase 2 development. Another of Arcellx’s biggest developments is a blood cancer immunotherapy awaiting FDA approval, with a decision expected by December 2026.
If the treatment is proven successful, it would be a major product in the healthcare space and a significant revenue generator for Arcellx. However, with the merger on the way, it’s difficult to say how long investors have to trade shares before the company is delisted.
